Posts Tagged ‘biotech’

  Over the last decade, the life sciences industry has gone from running clinical trials on paper or, in many cases, in Excel, to leveraging comprehensive web-based systems, such as electronic data capture (EDC) and clinical trial management systems (CTMS). But, in more recent years, the widespread use of mobile technology has enabled even more […]

  While we work in an industry in which we aim to treat patients, rich or poor, we live in a world where money is often deemed king. And, with an influx of financial investments pouring into newer pharmaceutical and biotechnology companies, people are jumping ship more than ever, making it harder for big pharma […]

  “…a news organization can be most nimble when it is built organically for the digital age.” – John Henry That’s what STAT is. John Henry, the owner of the The Boston Globe, Boston Red Sox, Liverpool Football Club, and Roush Fenway Racing, just launched a new digital publication that’ll solely cover the life sciences […]

Reading a recent LinkedIn Pulse post from Genentech’s VP of IT Americas, Cindy Elkins, made me smile. She said so many good things. Cindy discussed the IT landscape at the company, arguably the most famous biotech (ever!), and how the IT organization impacts employees and patients on many different levels. 

  Several months ago I posted Why Don’t I See Ads For Clinical Trials?, a piece in which I questioned just that. In a society where healthcare is always front and center, how is it that most of us are still unaware of our options when it comes to participating in clinical research? 

  Thanks to one of my LinkedIn contacts, I was introduced to a newly released “scorecard” that ranks pharmaceutical and biotechnology companies based on their precision medicine efforts. In essence, the organizations who made the cut are the ones moving precision medicine forward. They’re the ones focused on leveraging biomarkers to develop new therapies. 

  I’ve written a number of blog posts on the challenges of clinical trial recruitment, and that’s for good reason. According to Dr. Steven Alberts, Chair of Medical Oncology with the Mayo Clinic, only 5% of cancer patients ever enroll in a trial. On top of that, only a fraction of all trials ever complete […]

  A couple of weeks ago, I shared some statistics that I learned from an FDA blog post about rare diseases. While those numbers will make you cringe, Pfizer will give you hope. They, along with Spark Therapeutics, are teaming up to develop treatments for rare diseases, like hemophilia, through gene therapy. Gene therapy is […]

  In 2009, the cost for a consumer to sequence his or her genome was $49,000. It’s all the way down to $1,000 today. As the price continues to become more affordable, the frequency of the average Joe sequencing his genome will likely increase. However, many individuals are wary of the idea of knowing more […]

  Now that October is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in September – they’re ranked in order of popularity, with number one being the most viewed piece. 

Since the infamous Kim Kardashian Instagram post went up and the FDA issued a Warning Letter to Duchesnay, the company she was representing, a couple of things have happened. For one, Kim has issued a corrective post (i.e., ad), which outlined the safety information for Diclegis, the medication for morning sickness she is promoting. And, […]

  Turing Pharmaceuticals, the maker of Daraprim, a drug that treats toxoplasmosis (a parasitic disease), increased the cost of each tablet from $13.50 to $750. That’s right – more than a 5,000% increase.